
Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.
Patients' adherence ability is by far the top patient factor guiding selection of a first-line antiretroviral regimen for HIV, according to a new physician survey.






